Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 14/20 | 0.59 |
| ▸ | KIT | P10721 | 6/20 | 0.59 |
| ▸ | FLT3 | P36888 | 6/20 | 0.59 |
| ▸ | CDK7 | P50613 | 6/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13524974 | 0.90 | CHEK1 (0.57) | CHEK1KITFLT3CDK7NTRK1 | |
| SCHEMBL13524972 | 0.90 | CHEK1 (0.57) | CHEK1KITFLT3CDK7NTRK1 | |
| SCHEMBL13524975 | 0.84 | FLT3 (0.62) | CHEK1KITFLT3NTRK1SRC | |
| SCHEMBL13524978 | 0.84 | FLT3 (0.53) | CHEK1KITFLT3NTRK1SRC | |
| SCHEMBL13524920 | 0.83 | CHEK1 (0.64) | CHEK1KITFLT3CDK7 | |
| SCHEMBL13524977 | 0.78 | KIT (0.61) | KITFLT3NTRK1SRCKDR | |
| SCHEMBL13524914 | 0.76 | KIT (0.60) | CHEK1KITFLT3CDK7NTRK1 | |
| SCHEMBL24292329 | 0.76 | FLT3 (0.75) | CHEK1KITFLT3CDK7NTRK1 | |
| SCHEMBL13524980 | 0.75 | FLT3 (0.54) | KITFLT3NTRK1SRCKDR | |
| SCHEMBL3175850 | 0.75 | FLT3 (0.62) | KITFLT3NTRK1SRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009987-A1 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MERCK SHARP & DOHME LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100009987-A1 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MERCK SHARP & DOHME LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009987-A1 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MAPT, MARK4, MARK3 | CHEK1 494/4885KIT 3221/4885FLT3 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.